Replimune Group, Inc. (REPL): Cash & Equivalents
$209.02M
As of 2026-03-31
$185.36M
As of 2026-06-30
+12.6%
3-year compound annual growth
+2.7%
5-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2026-03-31 | $209.02M | +88.1% | 2026-06-29, Balance as of period end |
| 2025-03-31 | $111.12M | +49.2% | 2026-06-29, Balance as of period end |
| 2024-03-31 | $74.46M | -49.2% | 2025-05-22, Balance as of period end |
| 2023-03-31 | $146.59M | +38.4% | 2024-05-16, Balance as of period end |
| 2022-03-31 | $105.95M | -42.0% | 2023-05-18, Balance as of period end |
| 2021-03-31 | $182.52M | +206.8% | 2022-05-19, Balance as of period end |
| 2020-03-31 | $59.50M | +131.5% | 2021-05-20, Balance as of period end |
| 2019-03-31 | $25.70M | +46.2% | 2020-06-03, Balance as of period end |
| 2018-03-31 | $17.58M | n/a | 2019-06-28, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| Replimune Group, Inc. (REPL) | 2026-03-31 | $209.02M | +88.1% |
| Prokidney Corp. (PROK) | 2025-12-31 | $108.54M | +9.5% |
| Prime Medicine, Inc. (PRME) | 2025-12-31 | $63.03M | -65.5% |
| Taysha Gene Therapies, Inc. (TSHA) | 2025-12-31 | $319.77M | +130.0% |
| Fate Therapeutics Inc (FATE) | 2025-12-31 | $46.63M | +29.3% |
| Kodiak Sciences Inc. (KOD) | 2025-12-31 | $209.86M | +24.9% |
| C4 Therapeutics, Inc. (CCCC) | 2025-12-31 | $74.60M | +34.4% |
| LENZ Therapeutics, Inc. (LENZ) | 2025-12-31 | $25.18M | +24.9% |
| Scilex Holding Co (SCLX) | 2025-12-31 | $4.96M | +51.4% |
Compare REPL, PROK, PRME, TSHA side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗